Patient monitoring data systems market showing healthy growth
This article was originally published in Clinica
The European market for patient monitoring data management systems (DMS) is set to grow from an estimated $126.8m in 2009 to around $161.4m in 2013, according to a report published today by market analysts Frost & Sullivan.
You may also be interested in...
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.